Cochrane · systematic review · CD012021
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs
Platt, L, Minozzi, S, Reed, J, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Drugs and AlcoholAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current OST versus no OST for people who inject drugs
Population: people who inject drugs
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HCV incidence adjusted analyses number of HCV seroconversion Current OST vs no OST | RR 0.5 [0.4, 0.63] | 12 studies · 6361 participants | Low Downgraded: risk of bias |
High NSP coverage versus no/low NSP coverage for people who inject drugs
Population: people who inject drugs
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HCV incidence adjusted analyses number of HCV seroconversion High NSP coverage vs no/low NSP coverage | RR 0.79 [0.39, 1.61] | 5 studies · 3530 participants | Very low Downgraded: risk of bias, inconsistency |
Combined OST and high NSP versus no OST and low/no NSP for people who inject drugs
Population: people who inject drugs
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HCV incidence adjusted analyses number of HCV seroconversions Combined OST and high NSP vs no OST and low/no NSP | RR 0.26 [0.07, 0.89] | 3 studies · 3241 participants | Low Downgraded: risk of bias |